Leap Therapeutics amends CMO's severance; boosts benefits post-change-in-control

CYPHERPUNK TECHNOLOGIES INC.

CMO Cynthia Sirard gets 100% base salary severance (12 monthly installments) on non-Cause termination or Good Reason resignation.
Post-change-in-control termination within 1 year: severance increases to 125% base salary (lump sum) and COBRA reimbursed for 15 months (lump sum).
Equity awards become exercisable for up to 2 years after qualifying termination following a change in control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.